The global sales of medical hyperspectral imaging are estimated to be worth USD 204.3 million in 2024 and anticipated to reach a value of USD 359.0 million by 2034. Sales are projected to rise at a CAGR of 5.8% over the forecast period between 2024 and 2034. The revenue generated by medical hyperspectral imaging in 2023 was USD 193.1 million.
Cancers and chronic diseases are progressive conditions, and early detection is therefore crucial for successful treatment and better patient outcome. The increasing incidence of cancers and chronic diseases is one of the significant demand drivers for medical hyperspectral imaging, particularly in application tumor detection and surgery.
As the rates of cancer continue to increase in the world, advanced diagnostic equipment that uses precision, non-invasiveness, and early-stage diagnosis is of essence. In this respect, medical hyperspectral imaging is one of the most revolutionary technologies in sensing, in various ways, with which no other conventional imaging modality competes.
Global Medical Hyperspectral Imaging Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 193.1 million |
| Estimated Size, 2024 | USD 204.3 million |
| Projected Size, 2034 | USD 359.0 million |
| Value-based CAGR (2024 to 2034) | 5.8% |
Indeed, early diagnosis is the improvement in survival rates in cancer as it is the major cause of deaths around the world according to WHO, early detection allows for interventions that turn out to be far more effective. Conventional imaging methods like MRI, CT, and ultrasound normally provide poor contrasts between healthy and tumor tissues, especially regarding early-stage cancers.
The inability of these diagnostic capabilities from technologies available to this date has led to the need for more sensitive image-producing apparatus capable of the detection of cancer on a molecular level. Medical hyperspectral imaging caters to this very requirement by offering unprecedented spectral and spatial resolution.
Moreover, Cancer Research UK estimated that over 375,000 new cases of cancers have occurred in the UK annually of which roughly half were cancer of the breast, lung, prostate, and bowel.
Medical hyperspectral imaging differentiates between healthy and cancerous tissues, both preoperatively and intra-operatively. It therefore stands in great importance in the fight against cancer. The current rise in the burden of cancer across the world will see its demand for medical applications spur further development in hyperspectral imaging, hence improving outcomes further.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The below table presents the expected CAGR for the global medical hyperspectral imaging market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 6.6%, followed by a slightly lower growth rate of 6.2% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 6.6% (2023 to 2033) |
| H2 | 6.2% (2023 to 2033) |
| H1 | 5.8% (2024 to 2034) |
| H2 | 5.3% (2024 to 2034) |
The above table presents the expected CAGR for the global medical hyperspectral imaging market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 6.6%, followed by a slightly decline in growth rate of 6.2% in the second half (H2) of the same decade.
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 5.8% in the first half and increase moderately at 5.3% in the second half. In the first half (H1) the market witnessed a decrease of 80.00 BPS while in the second half (H2), the market witnessed a decrease of 90.00 BPS.
The Increasing Adoption of Hyperspectral Imaging in Dermatology Is Fueling Its Overall Market Growth
The increasing utilization of hyperspectral imaging within dermatology represents the key driver for market growth. As a field, dermatology encompasses a wide array of skin-related conditions wherein early detection or proper differential diagnosis needs to be performed.
Skin cancer and chronic wounds, among other disorders, depend on proper visualization and differentiation of healthy and abnormal tissue to correctly determine an individual's outcome. The special advantage of hyperspectral imaging is that it can provide highly detailed, real-time, and non-invasive images of skin layers and composition to improve the diagnostic accuracy of dermatological disorders and monitor the treatment in detail.
Canadian-based Photon etc. has developed the IR VIVO system, used in medical imaging, including dermatology. This hyperspectral imaging is very efficient in the detection of skin lesions, melanomas, and other skin abnormalities. Capturing the wide range of wavelength, it could map characteristics of skin tissue in great detail to help early diagnosis and treatment.
In conclusion, hyperspectral imaging is playing a crucial role in the management and treatment of chronic wounds, such as diabetic ulcers, pressure sores, and venous leg ulcers. Thus, dermatologists will have the ability with this technology to monitor tissue oxygenation, blood flow, inflammation, continuously presenting real-time data related to the tissue-healing process.
Real-Time Surgical Guidance Is the Key Factor for The Adoption of Medical Hyperspectral Imaging Market
Imaging modalities, such as MRI, CT, and ultrasound, are generally pre-operative planning modalities but carry significant limitations for real-time intraoperative guidance. These modalities yield static images that pre-operatively define the surgical arena but usually do not suffice intra-operatively. This limitation increases the need for real time surgical guidance.
Hyperspectral imaging provides real-time multispectral views of tissues, offering structural and functional information that will enhance surgical precision. Because it examines the manner by which tissues reflect light over a large range of wavelengths, hyperspectral imaging can detect subtle differences between healthy and diseased tissues, monitor blood flow, and assess tissue viability-all beyond the capabilities of traditional imaging modalities.
HinaLea Imaging has developed the HyperView™ hyperspectral system designed for real-time tissue analysis during surgery. It provides high spatial and spectral resolution to surgeons, thereby allowing them to view tissue oxygenation and perfusion during procedures. This tool applies to cancer surgery, vascular surgery, and other applications that involve real-time monitoring of tissue health.
This real-time guidance goes a long way in procedures like brain surgery, where precision at the millimeter level is the desired requirement. Hyperspectral imaging can help delineate between healthy brain tissue and tumors and thereby guide the surgeon through safe passage in those critical areas.
Significant Shift from 2D to 3D Imaging Modalities Is a Key Opportunity for The Medical Hyperspectral Imaging Market
The shift from conventional 2D imaging to cutting-edge 3D imaging presents a significant opportunity in the medical hyperspectral imaging market. Though 2D imaging modalities have been used in healthcare for several years for diagnostic and surgical purposes, they pose various limitations concerning depth perception, spatial resolution, and their thorough view of complex biological tissues. In contrast to this, 3D imaging provides a base and one added major view that augments the multi-planar dimensions of diagnosis and therapy planning.
3D hyperspectral imaging captures data from multiple layers of tissue, allowing for a more complete understanding of tissue structure and composition. This is particularly useful in procedures where accurate depth information is crucial, such as tumor resections or vascular surgeries. Traditional 2D imaging provides a flat representation of tissues, often limiting the depth of information available to the clinician.
Specim FX10 and FX17: These two hyperspectral imaging cameras from Specim produce high-resolution 3D tissue images. Both platforms are useful in medical diagnostics, providing depth details that are important for higher diagnostic and treatment planning accuracy.
In that respect, the shift to 3D from 2D imaging is a significant opportunity for the medical hyperspectral imaging market. 3D hyperspectral imaging is transforming the way clinicians approach medical diagnostics and treatment.
Complex Data Processing and Interpretation Arising as a Prominent Challenge for the Medical Hyperspectral Imaging Market
Hyperspectral imaging of tissues involves acquiring data across a wide range of wavelengths; thus, the highly detailed insights it provides into tissue composition are accurate. However, the most valuable information becomes compromised due to the huge data generated from this technique. The main challenges in this field arise due to the information overload and the use of sophisticated computational analysis tools and expertise that are required for its result interpretation.
Individual pixels can contain spectral information from hundreds of wavelengths; in general, files generated using this modality are many orders of magnitude larger and more complex than standard medical imaging such as MRI or CT scans. For example, a single hyperspectral image may comprise hundreds of spectral bands, each carrying key diagnostic information about the imaged tissue.
Knowledge required for interpreting hyperspectral images is highly specialized. Unlike other conventional medical imaging, where a trained radiologist or clinician can visually interpret the images, hyperspectral imaging produces complex spectral data, an interpretation that requires knowledge of the specific spectral signatures associated with different tissues. Also, the special training required for personnel to interpret the images acts as another deterrent in the application of HSI in clinical practices.
Principal Consultant
The global medical hyperspectral imaging industry recorded a CAGR of 4.4% during the historical period between 2019 and 2023. The growth of medical hyperspectral imaging industry was positive as it reached a value of USD 193.1 million in 2023 from USD 147.8 million in 2019.
The medical hyperspectral imaging market is continuously evolving, characterized by continuous technological advancements and wider applications in healthcare. Traditional hyperspectral imaging system applications mainly focus on space, military, and environmental purposes, and are rarely used for medical purposes because of the high cost and large size of equipment, making analysis of the complex data difficult.
As the technology evolved, improvements in sensor miniaturization, data processing algorithms, and machine learning made hyperspectral imaging more accessible for medical use. Early applications of hyperspectral imaging fell predominantly under research settings used to characterize tissues, detect diseases progression, and the like in studying conditions such as wound healing and burn injuries. At this stage, its clinical use remained limited due to the need for further validation and cost constraints.
In the future, the market of medical hyperspectral imaging is expected to experience the highest growth, with technologies getting compact, affordable, and integrated into point-of-care diagnostics. Artificial intelligence and machine learning will play an increasingly important role in the analysis of hyperspectral data, further accelerating its use in precision medicine by means of more accurate and timely diagnostics.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 46.7% in global market. These companies are industry leaders with advanced technological capabilities, extensive research and development efforts, and strong financial resources.
Robust distribution networks and strategic partnerships with healthcare providers and technology firms go on to strengthen this leading market position. Prominent companies in tier 1 include IMEC, Norsk Elektro Optikk, Galileo Group, Inc. and Gilden Photonics.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 26.7% market share. The medical hyperspectral imaging market is contributed to by tier 2 companies that have growing influence in the market. Most of the companies are focused on specific niche areas within the area of medical hyperspectral imaging.
A significant number of tier 2 companies focus on cost-effective solutions and strategic collaborations that increase their market reach. They invest in developing advanced devices and enhancing patient experience with the prime target of capturing segments of the market. Prominent companies in tier 2 include Resonon, XIMEA, Gooch & Housego and Chemlmage.
Finally, Tier 3 companies, such as Applied Spectral Imaging, Cubert, EVK DI Kerschhaggl, Headwall Photonics and FluxData. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the medical hyperspectral imaging market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, with higher market share through 2034. In Asia Pacific, India is projected to witness a CAGR of 6.6% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| China | 5.8% |
| India | 6.6% |
| USA | 1.8% |
| South Korea | 4.6% |
| Canada | 3.1% |
| Spain | 3.4% |
| Germany | 1.9% |
| France | 2.9% |
USA medical hyperspectral imaging market is poised to exhibit a CAGR of 1.8% between 2024 and 2034. Currently, it holds the highest share in the North America market, and the trend is expected to continue during the forecast period.
The USA market is driven by the advanced technology coupled with high consumer demand. One of the major reasons for this dominance is the leading role that the country plays in applying innovative technologies to medical science. Companies based in the USA represent some of the innovators when it comes to designing and developing highly sophisticated medical hyperspectral imaging, characterized by accurate regulation of imaging supports and integrated with cutting-edge features like automatic settings, real-time monitoring, and increased comfort for patients.
Apart from technological advancement, high demand from consumers in the USA is also a driver for market growth. The USA health system focuses on quality care and advanced solutions, which influences hospitals and healthcare facilities to search for the latest technologies in medical hyperspectral imaging.
China medical hyperspectral imaging market is poised to exhibit a CAGR of 5.8% between 2024 and 2034. Currently, it holds the highest share in the East Asian market, and the trend is expected to continue during the forecast period.
The Chinese companies have been at the leading edge of designing medical hyperspectral imaging among other advanced medical technologies. Thus, their innovative nature spawns into the development of sophisticated and efficient devices that meet the increased demands for advanced respiratory care. In addition, it improves the functionality and reliability of the medical hyperspectral imaging, thereby increasing their appeal to health caregivers.
The manufacturing lines in China have given technology companies the unprecedented manufacturing capability to build such medical hyperspectral imaging technology at low costs.
Cost advantages in production and supply management in the country drive down the cost of such devices, hence their increased accessibility in the region. Growth by technology companies leads to expanded distribution networks and after-sales services to facilitate wider market access within East Asia.
India’s medical hyperspectral imaging market is poised to exhibit a CAGR of 6.6% between 2024 and 2034. Currently, it holds the highest share in the Asia Pacific market, and the trend is expected to continue during the forecast period.
India is rapidly emerging as a strategic platform for medical research and innovation, with an increasing awareness relating to hyperspectral imaging to bring a revolution in health management. The outcome of hyperspectral imaging is visibly observed in oncology. In oncology, hyperspectral imaging is under extensive study for its capability to distinguish healthy from cancerous tissues based on their spectral signatures.
Indian research institutions. Some of them are at the frontline of research involving the use of HSI in detecting tumor margins with increased precision to further enhance the accuracy of cancer surgeries. Generally, local development of such technologies within India will reduce the dependence on imported imaging devices, making cancer care more affordable and accessible. This is further supported by collaborations between Indian academia and international medical device manufacturers.
The section contains information about the leading segments in the industry. By product, the hyperspectral imaging systems segment holds the highest market share of 63.5% in 2024.
| By Product | Hyperspectral Imaging Systems |
|---|---|
| Value Share (2024) | 63.5% |
Medical hyperspectral imaging systems are essential for diagnostics in a non-invasive manner in areas such as oncology, dermatology, and ophthalmology. Further, the possibility of differentiating between healthy and diseased tissues, based on the spectral of tissues, therefore allows early detection, precision monitoring, and even real-time assessment during surgical procedures.
Their application in the detection of diseases like skin cancer, the healing process of wounds, and tissue oxygenation has created demand in the healthcare segment and provides an edge to these systems over other medical imaging products.
Advances in sensor technology, data processing algorithms, and machine learning have ensured that hyperspectral systems are increasingly available, more reliable, and more accurate. These systems continue to become smaller, easier to interface into a clinical environment, and provide real-time imaging, a critical requirement for surgical guidance. This further cements their position as the leading product in the segment.
| By Application | Medical Diagnosis |
|---|---|
| Value Share (2024) | 33.6% |
Diagnosis accounts for the leading share of medical hyperspectral imaging systems. This technology is poised for a leading position in the medical hyperspectral imaging systems market, as it can produce highly detailed, non-invasive imaging helpful in diagnosing diseases at an early stage with great precision.
A hyperspectral imaging system captures data on a wide range of wavelengths, which is more closely discriminative of tissue compared to other conventional approaches like X-ray and MRI. This makes the diagnostic capability of HSI unmatched and very useful for diagnosing various conditions. Some of the critical areas in which this technique finds applications include oncology, dermatology, and ophthalmology.
The market players are imperatively employing strategic ways to compete and capture business shares, increasing product differentiation through new product launches and strategic acquisitions, and looking for strategic partners who can support them in widening their product portfolios for global market reach.
Recent Industry Developments in Medical Hyperspectral Imaging Market
In terms of product, the industry is divided into hyperspectral imaging systems and accessories.
In the terms of application, the market is segmented into medical diagnosis (ophthalmology, wound diagnostics, oncology, GI diseases and others), tissue and cell biology, drug discovery, others.
In terms of technology, the industry is divided into visible hyperspectral imaging, near-infrared hyperspectral imaging, ultraviolet hyperspectral imaging, short-wave infrared imaging and mid-wave infrared hyperspectral imaging.
In the terms of end user, the market is segmented into hospitals, diagnostic centres, pharmaceutical & biotechnology companies and research & academic centres.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global medical hyperspectral imaging market is projected to witness CAGR of 5.8% between 2024 and 2034.
The global medical hyperspectral imaging industry stood at USD 193.1 million in 2023.
The global medical hyperspectral imaging market is anticipated to reach USD 359.0 million by 2034 end.
India is set to record the highest CAGR of 6.6% in the assessment period.
The key players operating in the global medical hyperspectral imaging market include CytoViva, Inc., Resonon Inc., Headwall Photonics Inc., Corning Incorporated, SPECIM, Spectral Imaging Ltd., Norsk Elektro Optikk A/S, Merrick & Company, Kokuyo Camlin Ltd., Imec International, Telops Inc., Applied Spectral Imaging, BaySpec Inc., ChemImage Corporation, Brandywine Photonics LLC and FluxData Inc.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-Economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand (Value in USD) and Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market - Pricing Analysis 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. By Product 6.2. By Application 6.3. By Technology 6.4. By End User 6.5. By Region 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 7.1. Hyperspectral Imaging Systems 7.2. Accessories 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 8.1. Medical Diagnosis 8.1.1. Ophthalmology 8.1.2. Wound Diagnostics 8.1.3. Oncology 8.1.4. GI Diseases 8.1.5. Others 8.2. Tissue and Cell Biology 8.3. Drug Discovery 8.4. Others 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Technology 9.1. Visible Hyperspectral Imaging 9.2. Near-Infrared Hyperspectral Imaging 9.3. Ultraviolet Hyperspectral Imaging 9.4. Short-Wave Infrared Imaging 9.5. Mid-Wave Infrared Hyperspectral Imaging 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User 10.1. Hospitals 10.2. Diagnostic Centres 10.3. Pharmaceutical & Biotechnology Companies 10.4. Research & Academic Centres 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 11.1. North America 11.2. Latin America 11.3. Western Europe 11.4. Eastern Europe 11.5. South Asia & Pacific 11.6. East Asia 11.7. Middle East & Africa 12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 19. Sales Forecast 2024 to 2034 By Product, By Technology, By End User for 30 Countries 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 21. Company Profile 21.1. CytoViva, Inc. 21.2. Resonon Inc. 21.3. Headwall Photonics Inc. 21.4. Corning Incorporated 21.5. SPECIM, Spectral Imaging Ltd. 21.6. Norsk Elektro Optikk A/S 21.7. Merrick & Company 21.8. Kokuyo Camlin Ltd. 21.9. Imec International 21.10. Telops Inc. 21.11. Applied Spectral Imaging 21.12. BaySpec Inc. 21.13. ChemImage Corporation 21.14. Brandywine Photonics LLC 21.15. FluxData Inc.
Explore Healthcare Insights
View Reports
Medical Hyperspectral Imaging Market
